{
    "clinical_study": {
        "@rank": "25021", 
        "acronym": "MAIN", 
        "arm_group": [
            {
                "arm_group_label": "mycophenolate mofetil", 
                "arm_group_type": "Experimental", 
                "description": "mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan"
            }, 
            {
                "arm_group_label": "losartan", 
                "arm_group_type": "Active Comparator", 
                "description": "maximus tolerated labeled dose of losartan"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on\n      time to doubling of serum creatinine or the onset of end stage renal disease in patients\n      with advanced IgA nephropathy who are treated with the maximal tolerated daily dose of\n      losartan.The study will also assess the effects of MMF compared with losartan alone on the\n      changes of urine albumin excretion and the changes in estimated glomerular filtration rate."
        }, 
        "brief_title": "The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients", 
        "condition": "IgA Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy-proven primary IgA nephropathy with urinary proteinuria excretion over 1g/24\n             hour,subjects must meet 2 of the following criteria:\n\n               1. global glomerular sclerosis plus focal segmental glomerular sclerosis ratio \u226550%\n\n               2. eGFR 30-50 ml/min\n\n               3. Hypertension (blood pressure over 140/90 mmHg or taking antihypertensive drugs)\n\n        Exclusion Criteria:\n\n          1. Secondary IgA nephropathy\n\n          2. Familial IgA nephropathy\n\n          3. Concomitant disease: cancer, infection, diabetes mellitus, connective tissue disease,\n             abnormal liver function\n\n          4. Pregnancy or breasting\n\n          5. Inability to comply with study and follow-up procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "232", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854814", 
            "org_study_id": "MAIN"
        }, 
        "intervention": [
            {
                "arm_group_label": "mycophenolate mofetil", 
                "description": "Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "losartan", 
                "description": "Maximum tolerated labeled dose of Losartan", 
                "intervention_name": "Losartan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolate mofetil", 
                "Mycophenolic Acid", 
                "Losartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "wangjun1975@smu.edu.cn", 
                    "last_name": "Jun Wang, doctor", 
                    "phone": "0086-020-61641591"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510515"
                    }, 
                    "name": "Nanfang Hospital Southern Medical University"
                }, 
                "investigator": [
                    {
                        "last_name": "Min Liang, doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jun Wang, doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Xun Zhang, doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jun Ai, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Yangtcpro@163.com", 
                    "last_name": "Tiecheng Yang, MD", 
                    "phone": "008613823123966"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenzhen", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "518000"
                    }, 
                    "name": "The Fourth People's Hospital Shenzhen"
                }, 
                "investigator": {
                    "last_name": "Tiecheng Yang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hf-liu@263.net", 
                    "last_name": "Hua-feng Liu, PhD, MD", 
                    "phone": "0759-2387583"
                }, 
                "facility": {
                    "address": {
                        "city": "Zhanjiang", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "524001"
                    }, 
                    "name": "The Institute of Nephrology, Guangdong Medical College"
                }, 
                "investigator": {
                    "last_name": "Hua-feng Liu, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study", 
        "overall_contact": {
            "email": "ffhouguangzhou@163.com", 
            "last_name": "Fan Fan Hou, M.D.,PhD", 
            "phone": "0086-20-61641591"
        }, 
        "overall_official": {
            "affiliation": "Division of nephrology, Nanfang Hospital Southern Medical University", 
            "last_name": "Fan Fan Hou, M.D., PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to the first occurrence of a component of the composite renal endpoint:\nDoubling of serum creatinine or the onset of end stage renal disease (ESRD) [needing chronic dialysis or renal transplantation or renal death]", 
            "measure": "To evaluate the effects of mycophenolate mofetil on a composite renal outcomes in subjects with advanced IgA nephropathy", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "reference": [
            {
                "PMID": "20032964", 
                "citation": "Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010 Mar;77(6):543-9. doi: 10.1038/ki.2009.499. Epub 2009 Dec 23."
            }, 
            {
                "PMID": "16030050", 
                "citation": "Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005 Oct;20(10):2139-45. Epub 2005 Jul 19."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854814"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nanfang Hospital of Southern Medical University", 
            "investigator_full_name": "Fan Fan Hou", 
            "investigator_title": "Chief of Division of Nephrology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes of urinary protein excretion rate", 
                "measure": "To evaluate the effects of mycophenolate mofetil on the changes of proteinuria in subjects with advanced IgA nephropathy", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Time to 30% reduction in estimated glomerular filtration rate (eGFR); Changing from chronic kidney disease stage 3 to stage 4 using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula; eGFR reduction greater than 5 ml/min/1.73m^2/year;", 
                "measure": "To evaluate the effects of mycophenolate mofetil on  composite changes of renal function in subjects with advanced IgA nephropathy", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Nanfang Hospital of Southern Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fan Fan Hou", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}